Panacea Biotec Ltd. News and Updates

Keep track of all breaking news on Panacea Biotec Ltd. from all sources in a single place.

Panacea Biotec Ltd.

03 Jan 2025

394.55

0.36%

Panacea Biotec Shares Jump Over 5% After Announcement Of Baby Diaper Brand

NDTV Profit

The baby diaper brand will cater to the domestic market at present, but Panacea Biotec has plans to sell the products in other countries in 'due course'.

Panacea Biotec Ltd. is trading above all available SMAs

Panacea Biotec Ltd.

26 Dec 2024

394.55

0.36%

Multibagger small-cap stock hits 5% upper circuit on order win from UNICEF. Do you own?

livemint

Following a UNICEF order worth 127 crore, Panacea Biotec shares increased 5% to 456.25. The stock has seen substantial growth in recent times, up 225% over the last six months and 167 per cent year-to-date (YTD).

Panacea Biotec Ltd. has gained 24.12% in the last 6 Months

Why Panacea Biotec shares were locked in 5% upper circuit on Thursday?

Business Standard | 26 Dec 2024

Panacea Biotec Ltd.

11 Oct 2024

394.55

0.36%

Panacea Biotec surges 4% on reports of launching dengue vaccine in two yrs

Business Standard

Shares of Panacea Biotec surged up to 4.48 per cent at Rs 319.40 on the BSE in Friday's intraday trade

Panacea Biotec Ltd. is trading above all available SMAs

Panacea Biotec Ltd.

17 Sep 2024

394.55

0.36%

Panacea Biotec Hits Highest Level In Over Three Years As Company Settles Patent Dispute With Sanofi

NDTV Profit

The dispute involved Panacea Biotec's patented vaccine, EasySix, the first fully liquid hexavalent vaccine used for treatment of polio, tetanus, and diphtheria.

Panacea Biotec Ltd. has gained 24.12% in the last 6 Months

Panacea Biotec, Sanofi Settle Patent Dispute Over Hexavalent Vaccine

NDTV Profit | 16 Sep 2024

Panacea Biotec Ltd.

13 Sep 2024, 11:28AM

394.55

0.36%

Panacea Biotec gets $20 mn loan from US DFC for capex; stock rises 5%

Business Standard

The shares of Panacea Biotec rose after the company announced that it has secured $20 million in loan from US International Development Finance Corp (DFC).

Panacea Biotec Ltd. has gained 24.12% in the last 6 Months

DFC commits long-term loan of $20 mn to Panacea Biotec to expand operations

Business Standard | 12 Sep 2024

Panacea Biotec Ltd.

09 Sep 2024

394.55

0.36%

Panacea Biotec freezes in 10% upper circuit; stock zooms 101% in 1 month

Business Standard

A combined 2.1 million equity shares of the company had changed hands till 02:50 PM, and there are pending buy orders for nearly 100,000 shares on the NSE and BSE.

Panacea Biotec Ltd. has gained 24.12% in the last 6 Months

Panacea Biotec Ltd.

14 Aug 2024

394.55

0.36%

ICMR/Panacea Biotec dengue vaccine starts advanced phase-3 trials

Business Line

First participant on the Phase III trial vaccinated at PGIMS, Rohtak

Panacea Biotec Ltd. is trading above all available SMAs

Panacea Biotec Ltd.

14 Aug 2024

394.55

0.36%

to see Rapid results content

Panacea Biotec Ltd.

14 Aug 2024, 05:00PM

394.55

0.36%

Dengue vaccine: First-ever phase 3 clinical trial initiated in India

Business Standard

The ICMR and Panacea Biotec have initiated the first-ever phase three clinical trial for developing a dengue vaccine in India, the Union Health Ministry said on Wednesday. India's indigenous tetravalent dengue vaccine, DengiAll, has been developed by Panacea Biotec and the first participant in this trial was vaccinated on Wednesday at the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak. The phase three clinical trial will be conducted across 19 sites in 18 states and union territories, involving more than 10,335 healthy adult participants. "The initiation of this phase three clinical trial for India's first indigenous dengue vaccine marks a critical advancement in our fight against dengue. It reflects our commitment to protecting our citizens from this pervasive disease and underscores India's capabilities in vaccine research and development," Union Health Minister J P Nadda said. "Through this collaboration between ICMR and Panacea Biotec, we are no